[Molecular Mechanisms for Adhesion and Colonization of Human Gastric Mucosa by Helicobacter pylori and its Clinical Implications]

Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of Helicobacter pylori infections

Due to the high adaptability of Helicobacter pylori and the low targeting specificity of the drugs normally used in pharmacological therapy, the strains are becoming increasingly resistant to these drugs, making it difficult to eradicate the infection. Thus, the search for new therapeutic approaches has been considered urgent. The incorporation of drugs in advanced drug delivery systems, such as nano and microparticles, would allow the improvement of the retention time in the stomach and the prolongation of drug release rates at the target site. Because of this, the present review article aims to highlight the use of micro and nanoparticles as important technological tools for the treatment of H. pylori infections, focussing on the main nanotechnological systems, including nanostructured lipid carriers, liposomes, nanoemulsion, metallic nanoparticles, and polymeric nanoparticles, as well as microtechnological systems such as gastroretentive dosage forms, among them mucoadhesive, magnetic and floating systems were highlighted.

ABH and Lewis blood group systems and their relation to diagnosis and risk of Helicobacter pylori infection

BACKGROUND

Helicobacter pylori infection occurs in 50% of the world's population and represents a major risk factor for chronic gastritis, gastroduodenal ulcer and gastric cancer in developed and developing countries. The distribution of H. pylori virulence factors is diverse and varies geographically, such as the CagA and VacA genes, which have revealed association with disease status. Some findings show increased frequencies of these diseases in O Le (a-b +) and A Le (a-b +) blood type individuals, but other studies not found any relationship between these blood groups and H. pylori infection.

AIM

This study aimed to elucidate probable controversies described in the relationship between the ABH/Lewis blood groups and H. pylori, contributing to the severity of gastric diseases in northern the population of Belém -Pará.-Brazil.

METHODS

This cross-sectional study included 288 samples of patients separate into two groups with gastric cancer and chronic gastritis. Blood, saliva, and gastric biopsy were analyzed using modified Gram and hematoxylin-eosin staining techniques, the enzyme immunoassay Elisa and Multiplex PCR. The antigens expression of ABH and Lewis systems was determined through Dot-ELISA and direct hemagglutination. Proportions were compared in univariate analysis, while the relation between putative risk factors including H. pylori status and ABO/Lewis phenotype was performed using multivariable logistic regression analyses, P-value < 0.05 was considered significant.

RESULTS

The findings of this study demonstrate that the likelihood of developing gastric cancer increases threefold if the individual is from A1 Le (a-b +) blood group, has premalignant changes, and infection with H. pylori virulent strains (cagA+/vacA + s1m1).

CONCLUSION

Therefore, this study found a significant association between ABO and Lewis phenotypes and H. pylori cagA status into the relevance of the development of gastric carcinogenesis.

Clinical significance of expression of proliferating cell nuclear antigen and E-cadherin in gastric carcinoma

AIM

to investigate the expression of proliferating cell nuclear antigen (PCNA) and E-cadherin in gastric carcinoma and to analyze their clinical significance.

METHODS

A total of 146 patients were selected for this study, including 38 patients with intestinal metaplasia, 42 with dysplasia, and 66 with primary gastric cancer. In addition, 40 patients with normal gastric tissues were selected as controls. The expression of PCNA and E-cadherin was detected by immunohistochemistry. Differences in PCNA and the E-cadherin labeling indexes among normal gastric mucosa, intestinal metaplasia, dysplasia, and gastric carcinoma were compared. Subjects with normal gastric tissues were assigned to a normal group, while gastric cancer patients were assigned to a gastric cancer group. The difference in PCNA and E-cadherin expression between these two groups was compared. The relationship between expression of PCNA and E-cadherin and clinicopathological features was also explored in gastric cancer patients. Furthermore, prognosis-related factors, as well as the expression of PCNA and E-cadherin, were analyzed in patients with gastric cancer to determine the 3-year survival of these patients.

RESULTS

The difference in PCNA and the E-cadherin labeling indexes among normal gastric mucosa, intestinal metaplasia, dysplasia, and gastric carcinoma was statistically significant (P < 0.05). During the transition of normal gastric mucosa to gastric cancer, the PCNA labeling index gradually increased, while the E-cadherin labeling index gradually decreased (P < 0.05). The PCNA labeling index was significantly higher and the E-cadherin labeling index was significantly lower in gastric cancer than in dysplasia (P < 0.05). The expression of PCNA was significantly higher in the gastric cancer group than in the normal group, but E-cadherin was weaker (P < 0.05). There was a negative correlation between the expression of PCNA and E-cadherin in gastric carcinoma (r = -0.741, P = 0.000). PCNA expression differed significantly between gastric cancer patients with and without lymph node metastasis and between patients at different T stages. E-cadherin expression also differed significantly between gastric cancer patients with and without lymph node metastasis (P < 0.05). High T stage and positive PCNA expression were risk factors for the prognosis of patients with gastric cancer (RR > 1), while the positive expression of E-cadherin was a protective factor (RR < 1). The sensitivity, specificity, and accuracy of PCNA positivity in predicting the 3-year survival of patients with gastric cancer were 93.33%, 38.89%, and 0.64, respectively; while these values for E-cadherin negativity were 80.0%, 41.67%, and 0.59, respectively. When PCNA positivity and E-cadherin negativity were combined, the sensitivity, specificity, and accuracy were 66.67%, 66.67%, and 0.67, respectively.

CONCLUSION

Combined detection of PCNA and E-cadherin can improve the accuracy of assessing the prognosis of patients with gastric cancer.